Certolizumab Pegol Is Associated With Long-Term Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: 4-Year Outcomes From the Rapid-Psa Study

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.1426

Related search